Orthofix (OFIX) Q2 Revenue Rises 2%
Financial Performance: Orthofix Medical reported a GAAP earnings loss of $(0.36) per share for Q2 2025, which was better than expected, alongside revenue of $203.1 million, marking a 2.3% year-over-year growth and surpassing analyst estimates.
Business Strategy and Growth Areas: The company is focusing on new product launches and optimizing distribution, with notable growth in Bone Growth Therapies and Orthopedics segments, while also managing ongoing operational risks and restructuring costs.
Trade with 70% Backtested Accuracy
Analyst Views on OFIX
About OFIX
About the author
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Bone Grafts Market Report: Forecast to 2036
- Market Size Forecast: The report indicates significant growth in the bone grafts and substitutes market projected by 2036, with detailed intervention volumes and market value data across 39 countries aiding strategic decision-making for businesses.
- Product Segmentation Analysis: It provides an in-depth analysis of various bone graft substitutes, including allograft bone chips and bone morphogenetic proteins, offering insights into market share and average selling prices to help companies optimize their product portfolios.
- Competitive Dynamics Insights: Through SWOT analysis and exploration of competitive dynamics, the report reveals the market positions of key players such as Medtronic and Stryker, assisting investors in identifying potential investment opportunities.
- Market Access Strategies: Additionally, the report offers detailed information on market access, including reimbursement policies and regulatory landscapes, enabling companies to formulate effective market entry strategies in a complex environment.
Orthofix CEO Massimo Calafiore Sells 19,397 Shares
- Executive Sell-off: Orthofix CEO Massimo Calafiore sold 19,397 shares on January 9, 2026, which may raise concerns about the company's future prospects and impact investor confidence.
- Impact of Share Movement: The significant number of shares sold could be interpreted by the market as a lack of confidence in the company's current valuation or future performance, potentially exerting negative pressure on the stock price.
- Market Reaction Expectations: The market may react negatively to this sell-off, prompting investors to reassess Orthofix's investment value, leading to increased stock price volatility in the short term.
- Transparency and Trust: The executive's sell-off could raise questions about the company's governance transparency, affecting investor trust in the management team and potentially impacting long-term shareholder value.
Orthofix Medical Inc. Reports Reduced Losses in Q3
Third Quarter Loss: Orthofix Medical Inc. reported a loss of -$22.80 million for the third quarter, an improvement from -$27.39 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) were -$0.57, compared to -$0.71 in the previous year.
Revenue Growth: Revenue increased by 4.6% to $205.63 million, up from $196.61 million year-over-year.
Sales Guidance Update: Orthofix has narrowed its fiscal year 2025 net sales guidance to a range of $810 million to $814 million.
Significant Options Activity on Wednesday: DUOL, ORCL, OFIX
Oracle Corp Options Trading: Oracle Corp (ORCL) experienced a significant options trading volume of 191,199 contracts, equating to about 19.1 million underlying shares, with a notable focus on the $300 strike call option expiring on October 31, 2025.
Orthofix Medical Inc Options Activity: Orthofix Medical Inc (OFIX) saw options trading of 2,000 contracts, representing approximately 200,000 underlying shares, with high activity in the $15 strike put option expiring on November 21, 2025.
Comparison of Trading Volumes: The options trading volumes for both ORCL and OFIX reflect a substantial percentage of their average daily trading volumes over the past month, indicating heightened investor interest.
Further Information: For additional details on available expirations for DUOL, ORCL, or OFIX options, resources can be found at StockOptionsChannel.com.
Barrington Research Reaffirms Outperform Rating for Orthofix Medical, Keeps $17 Price Target Intact
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Bone Grafts Market Report: Forecast to 2036
- Market Size Forecast: The report indicates significant growth in the bone grafts and substitutes market projected by 2036, with detailed intervention volumes and market value data across 39 countries aiding strategic decision-making for businesses.
- Product Segmentation Analysis: It provides an in-depth analysis of various bone graft substitutes, including allograft bone chips and bone morphogenetic proteins, offering insights into market share and average selling prices to help companies optimize their product portfolios.
- Competitive Dynamics Insights: Through SWOT analysis and exploration of competitive dynamics, the report reveals the market positions of key players such as Medtronic and Stryker, assisting investors in identifying potential investment opportunities.
- Market Access Strategies: Additionally, the report offers detailed information on market access, including reimbursement policies and regulatory landscapes, enabling companies to formulate effective market entry strategies in a complex environment.
Orthofix CEO Massimo Calafiore Sells 19,397 Shares
- Executive Sell-off: Orthofix CEO Massimo Calafiore sold 19,397 shares on January 9, 2026, which may raise concerns about the company's future prospects and impact investor confidence.
- Impact of Share Movement: The significant number of shares sold could be interpreted by the market as a lack of confidence in the company's current valuation or future performance, potentially exerting negative pressure on the stock price.
- Market Reaction Expectations: The market may react negatively to this sell-off, prompting investors to reassess Orthofix's investment value, leading to increased stock price volatility in the short term.
- Transparency and Trust: The executive's sell-off could raise questions about the company's governance transparency, affecting investor trust in the management team and potentially impacting long-term shareholder value.
Orthofix Medical Inc. Reports Reduced Losses in Q3
Third Quarter Loss: Orthofix Medical Inc. reported a loss of -$22.80 million for the third quarter, an improvement from -$27.39 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) were -$0.57, compared to -$0.71 in the previous year.
Revenue Growth: Revenue increased by 4.6% to $205.63 million, up from $196.61 million year-over-year.
Sales Guidance Update: Orthofix has narrowed its fiscal year 2025 net sales guidance to a range of $810 million to $814 million.
Significant Options Activity on Wednesday: DUOL, ORCL, OFIX
Oracle Corp Options Trading: Oracle Corp (ORCL) experienced a significant options trading volume of 191,199 contracts, equating to about 19.1 million underlying shares, with a notable focus on the $300 strike call option expiring on October 31, 2025.
Orthofix Medical Inc Options Activity: Orthofix Medical Inc (OFIX) saw options trading of 2,000 contracts, representing approximately 200,000 underlying shares, with high activity in the $15 strike put option expiring on November 21, 2025.
Comparison of Trading Volumes: The options trading volumes for both ORCL and OFIX reflect a substantial percentage of their average daily trading volumes over the past month, indicating heightened investor interest.
Further Information: For additional details on available expirations for DUOL, ORCL, or OFIX options, resources can be found at StockOptionsChannel.com.
Barrington Research Reaffirms Outperform Rating for Orthofix Medical, Keeps $17 Price Target Intact
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
